Future of an 'asymptomatic' T-cell epitope-based therapeutic herpes simplex vaccine

Future Virology

Volumn 7, Issue 4, 2012, Pages 371-378

  Dervillez, Xavier ^a   Gottimukkala, Chetan ^a   Kabbara, Khaled W ^a   Nguyen, Chelsea ^a   Badakhshan, Tina ^a   Kim, Sarah M ^a   Nesburn, Anthony B ^a   Wechsler, Steven L ^a   Benmohamed, Lbachir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antigen; asymptomatic; epitope; herpes; HSV 1; HSV 2; human; symptomatic; T cell; therapeutic; vaccine

Indexed keywords

HERPES SIMPLEX VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; T LYMPHOCYTE ANTIGEN; VIRUS ANTIGEN;

ANTIBODY RESPONSE; ASYMPTOMATIC INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG SYNTHESIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INNATE IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; VIRUS LATENCY; VIRUS REACTIVATION;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 84859406306     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.22     Document Type: Review

References (93)

1. Chentoufi AA, Dasgupta G, Christensen ND et al. A novel HLA (HLA-A.0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J. Immunol. 184(5), 2561-2571 (2010
2. Chentoufi AA, Dasgupta G, Nesburn AB et al. Nasolacrimal duct closure modulates ocular mucosal and systemic CD4+ T-cell responses induced following topical ocular or intranasal immunization. Clin. Vaccine Immunol. 17(3), 342-353 (2010
3. Dasgupta G, Nesburn AB, Wechsler SL, BenMohamed L. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol. 5(1), 1-4 (2010
4. Whitley RJ, Miller RL. Immunologic approach to herpes simplex virus. Viral Immunol. 14(2), 111-118 (2001
5. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 357(9267), 1513-1518 (2001
6. BenMohamed L, Bertrand G, McNamara CD et al. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77(17), 9463-9473 (2003
7. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2(7), 425-431 (2002
8. Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB, Benmohamed L. Thcytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J. Virol. 79(24), 15289-15301 (2005
9. Bettahi I, Zhang X, Afifi RE, Benmohamed L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuVanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol. 19(2), 220-236 (2006
10. Nesburn AB, Bettahi I, Zhang X et al. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4(4), 178-187 (2006
11. Dana MR, Qian Y, Hamrah P. Twenty-fiveyear panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 19(5), 625-643 (2000
12. Smith JS, Herrero R, Bosetti C et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl Cancer Inst. 94(21), 1604-1613 (2002
13. Whitley RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J. Clin. Invest. 110(2), 145-151 (2002
14. Guillaume JC. [Antiviral and non-antiviral general treatments for oro-facial and genital herpes (pregnancy and neonates excluded)]. Ann. Dermatol. Venereol. 129(4 Pt 2), 625-634 (2002
15. Kriesel JD, Jones BB, Matsunami N et al. C21orf91 genotypes correlate with herpes simplex labialis (cold sore) frequency: description of a cold sore susceptibility gene. J. Infect. Dis. 204(11), 1654-1662 (2011
16. Xu F, Sternberg MR, Kottiri BJ et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296(8), 964-973 (2006
17. Fleming DT, Mcquillan GM, Johnson RE et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337(16), 1105-1111 (1997
18. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 86(10), 805-812 (2008
19. Kalantari-Dehaghi M, Chun S, Chentoufi AA et al. Discovery of potential diagnostic and vaccine antigens in herpes simplex virus-1 and -2 by proteome-wide antibody profiling. J. Virology doi:10.1128/JVI.05194-11 (2012) (Epub ahead of print
20. Chentoufi AA, Kritzer E, Nesburn AB, Benmohamed L. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin. Develop. Immunol. (2012) (In Press
21. Kimberlin DW, Whitley RJ, Wan W et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N. Engl. J. Med. 365(14), 1284-1292 (2011
22. Brown ZA, Gardella C, Wald A, Morrow RA, Corey L. Genital herpes complicating pregnancy. Obstet. Gynecol. 106(4), 845-856 (2005
23. Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N. Engl. J. Med. 361(14), 1376-1385 (2009
24. Kimberlin DW, Rouse DJ. Clinical practice. Genital herpes. N. Engl. J. Med. 350(19), 1970-1977 (2004
25. Dasgupta G, BenMohamed L. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8+-T cell-epitopesbased immunotherapeutic vaccine candidates? Vaccine 29(35), 5824-5836 (2011
26. SulliVan-Bolyai JZ, Hull HF, Wilson C, Smith AL, Corey L. Presentation of neonatal herpes simplex virus infections: implications for a change in therapeutic strategy. Pediatr. Infect. Dis. 5(3) 309-314 (1986
27. Chentoufi AA, Kritzer E, Tran MV et al. The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. J. Virol. 85(17), 9127-9138 (2011
28. Chentoufi AA, Dervillez X, Dasgupta G et al. The herpes simplex virus type 1 latency associated transcript inhibits phenotypic and functional maturation of dendritic cells. Viral Immunol. (2012) (In Press
29. Swetter SM, Hill EL, Kern ER et al. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. J. Infect. Dis. 177(3), 543-550 (1998
30. Perng G C, Jones C, Ciacci-Zanella J et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 287(5457), 1500-1503 (2000
31. Dasgupta G, Chentoufi AA, Kalantari- Dehaghi M et al. Immunodominant 'asymptomatic' herpes simplex virus type 1 and type 2 protein antigens identified by probing whole ORFome microarrays by serum antibodies from seropositive asymptomatic versus symptomatic individuals. J. Virol. doi:10.1128/JVI.07107-11 (2012) (Epub ahead of print
32. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Invest. 99(5), 1092-1097 (1997
33. Knaup B, Schunemann S, Wolff MH. Subclinical reactivation of herpes simplex virus type 1 in the oral cavity. Oral Microbiol. Immunol. 15(5), 281-283 (2000
34. Wald A, Zeh J, Selke S et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N. Engl. J. Med. 342(12), 844-850 (2000
35. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin. Infect. Dis. 35(Suppl. 2), S173-S182 (2002
36. Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N. Engl. J. Med. 339, 300-306 (1998
37. Leigh JF, Acharya N, Cevallos V, Margolis TP. Does asymptomatic shedding of herpes simplex virus on the ocular surface lead to false-positive diagnostic PCR results? Br. J. Ophthalmol. 92(3), 435-436 (2008
38. Freeman ML, Sheridan BS, Bonneau RH, Hendricks RL. Psychological stress compromises CD8+ T cell control of latent herpes simplex virus type 1 infections. J. Immunol. 179(1), 322-328 (2007
39. Tronstein E, Johnston C, Huang Ml et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 305(14), 1441-1449 (2011
40. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest. Ophthalmol. Vis. Sci. 46(1), 241-247 (2005
41. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 20(1), 1-13 (2001
42. Chentoufi AA, Binder NR, Berka N et al. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82(23), 11792-11802 (2008
43. Koelle DM. Vaccines for herpes simplex virus infections. Curr. Opin. Investig. Drugs 7(2), 136-141 (2006
44. Geiss BJ, Smith TJ, Leib DA, Morrison LA. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain. J. Virol. 74(23), 11137-11144 (2000
45. Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J. Invest. 121(12), 4600-4609 (2011
46. Oxman MN. Zoster vaccine: current status and future prospects. Clin. Infect. Dis. 51(2), 197-213 (2010
47. Weinberg A, Zhang JH, Oxman MN et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J. Infect. Dis. 200(7), 1068-1077 (2009
48. Dasgupta G, Nesburn AB, Wechsler SL, Benmohamed L. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol. 5, 1-4 (2010
49. Rajcani J, Durmanova V. Developments in herpes simplex virus vaccines: old problems and new challenges. Folia Microbiol. (Praha) 51(2), 67-85 (2006
50. Eriksson K, Bellner L, Gorander S et al. CD4+ T-cell responses to herpes simplex virus type 2 (HSV-2) glycoprotein G are type specific and differ in symptomatic and asymptomatic HSV-2-infected individuals. J. Gen. Virol. 85(Pt 8), 2139-2147 (2004
51. Tigges MA, Koelle D, Hartog K, Sekulovich RE, Corey L, Burke RL. Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J. Virol. 66(3), 1622-1634 (1992
52. Stanberry LR. Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model. Rev. Infect. Dis. 13(Suppl. 11), S920-S923 (1991
53. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 17(13-14), 1681-1689 (1999
54. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11(Suppl. 3), 161A-169A (2004
55. De Bruyn G, Vargas-Cortez M, Warren T et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24(7), 914-920 (2006
56. Da Costa XJ, Morrison LA, Knipe DM. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 288(2), 256-263 (2001
57. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J. Virol. 74(17), 7963-7971 (2000
58. Da Costa XJ, Jones CA, Knipe DM. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc. Natl Acad. Sci. USA 96(12), 6994-6998 (1999
59. Da Costa XJ, Bourne N, Stanberry LR, Knipe DM. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 232(1), 1-12 (1997
60. Spector FC, Kern ER, Palmer J et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J. Infect. Dis. 177(5), 1143-1154 (1998
61. Branco FJ, Fraser NW. Herpes simplex virus type 1 latency-associated transcript expression protects trigeminal ganglion neurons from apoptosis. J Virol 79(14), 9019-9025 (2005
62. Prichard MN, Kaiwar R, Jackman WT et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23(46-47), 5424-5431 (2005
63. Reszka NJ, Dudek T, Knipe DM. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 28(15), 2754-2762 (2010
64. Liu J, O'Brien Kl, Lynch DM et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457(7225), 87-91 (2009
65. Hoshino Y, Pesnicak L, Dowdell KC et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26(32), 4034-4040 (2008
66. Dudek T, Mathews LC, Knipe DM. Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 372(1), 165-175 (2008
67. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 344(1), 230-239 (2006
68. Hoshino Y, Qin J, Follmann D, Cohen JI, Straus SE. The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia. Virology 372(1), 56-63 (2008
69. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit Vaccine PLoS One 6(3), E17748 (2011
70. Halford WP, Puschel R, Rakowski B. Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes Vaccine PLoS One 5(8), E12251 (2010
71. Halford WP, Weisend C, Grace J et al. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol. J. 3, 44 (2006
72. Franchini M, Hefti H, Vollstedt S et al. Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice. J. Immunol. 172(10), 6304-6312 (2004
73. Abril C, Engels M, Liman A et al. Both viral and host factors contribute to neurovirulence of bovine herpesviruses 1 and 5 in interferon receptor-deficient mice. J. Virol. 78(7), 3644-3653 (2004
74. Franchini M, Abril C, Schwerdel C, Ruedl C, Ackermann M, Suter M. Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus. J. Virol. 75(1), 83-89 (2001
75. Osorio Y, Cohen J, Ghiasi H. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Invest. Ophthalmol. Vis. Sci. 45(2), 506-514 (2004
76. Ghiasi H, Cai S, Slanina S, Nesburn AB, Wechsler SL. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res. 28(2), 147-157 (1995
77. Pardoe I, Dargan D. PREPS and L-particles: a new approach to virus-like particle vaccines. Expert Rev. Vaccines 1(4), 427-432 (2002
78. Muller WJ, Dong L, Vilalta A et al. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J. Gen. Virol. 90, 1153-1163 (2009
79. Muller WJ, Orgun NN, Dong L, Koelle DM, Huang ML, Way SS. Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2. Arch. Virol. 153(6), 1165-1169 (2008
80. Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuVant vaccine to prevent genital herpes. N. Engl. J. Med. 347(21), 1652-1661 (2002
81. BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuVant. Eur. J. Immunol 32(8), 2274-2281 (2002
82. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuVant induces systemic immune responses. Immunology 106(1), 113-121 (2002
83. Bourne N, Bravo FJ, Francotte M et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis. 187(4), 542-549 (2003
84. Belshe PB, Leone PA, Bernstein DI et al. Efficacy results of a trial of a herpes simplex Vaccine N. Engl. J. Med. 366, 34-43 (2012
85. Zhang X, Chentoufi AA, Dasgupta G et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2(2), 129-143 (2009
86. Corey L, Langenberg AG, Ashley R et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4), 331-340 (1999
87. Hartley C. Immunologic strategies for herpes vaccination. JAMA 283(6), 746; author reply 746-747 (2000
88. Friedman HM. Immunologic strategies for herpes vaccination. JAMA 283(6), 746; author reply 746-747 (2000
89. Chentoufi AA, BenMohamed L. Future viral vectors for the delivery of asymptomatic herpes epitopes-based immunotherapeutic vaccines. Future Virol. 5, 1-4 (2010
90. Chentoufi AA, Zhang X, Lamberth K et al. HLA-A.0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180(1), 426-437 (2008
91. Zhang X, Castelli FA, Zhu X, Wu M, Maillere B, BenMohamed L. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin. Vaccine Immunol. 15(9), 1436-1449 (2008
92. Kim SK, Cornberg M, Wang XZ, Chen HD, Selin LK, Welsh RM. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J. Exp. Med. 201(4), 523-533 (2005
93. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat. Rev. Immunol. 2(6), 417-426 (2002)